Skip to results

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1 to 50 of 383

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]Technology appraisal guidanceTBC
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]Technology appraisal guidanceTBC
Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]Technology appraisal guidanceTBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]Technology appraisal guidanceTBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Technology appraisal guidanceTBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]Technology appraisal guidanceTBC
Acute kidney injury: prevention, detection and management - Assessing risk factors for acute kidney injury in adults having iodine-based contrast mediaNICE guideline
Adrenal insufficiency: identification and managementNICE guideline
Alcohol-mediated perivascular renal denervation for resistant hypertensionInterventional procedures guidance
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]Technology appraisal guidance
ALXN1840 for treating Wilson disease TS ID 9950Technology appraisal guidanceTBC
Alzheimer's disease (early) - gantenerumab [ID6142]Technology appraisal guidanceTBC
Amyotrophic lateral sclerosis - SAR443820 [ID6386]Technology appraisal guidanceTBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Technology appraisal guidance
Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]Technology appraisal guidanceTBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]Technology appraisal guidanceTBC
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]Highly specialised technologyTBC
Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathwayHealth technology evaluationTBC
Artificial intelligence software to help detect fractures in the emergency department (provisional title)Health technology evaluation
Asthma: diagnosis, monitoring and chronic asthma managementNICE guidelineTBC
Asunercept for treating glioblastoma [1301]Technology appraisal guidanceTBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]Technology appraisal guidanceTBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Technology appraisal guidanceTBC
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]Technology appraisal guidanceTBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]Technology appraisal guidanceTBC
Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]Technology appraisal guidanceTBC
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]Technology appraisal guidanceTBC
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma [ID6325]Technology appraisal guidance
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]Technology appraisal guidanceTBC
Avapritinib for treating advanced systemic mastocytosis ID3770Technology appraisal guidanceTBC
Avelumab for previously treated platinum-resistant ovarian cancer ID1497Technology appraisal guidanceTBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]Technology appraisal guidanceTBC
Baricitinib for treating juvenile idiopathic arthritis in children and young people aged 1 to 17 [ID6143]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]Technology appraisal guidanceTBC
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]Technology appraisal guidanceTBC
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212Technology appraisal guidance
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211Technology appraisal guidanceTBC
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]Technology appraisal guidanceTBC
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]Technology appraisal guidanceTBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]Technology appraisal guidanceTBC
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]Technology appraisal guidance
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]Technology appraisal guidanceTBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]Technology appraisal guidance
Bipolar disorder: assessment and management (extraordinary review)NICE guidelineTBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405Health technology evaluationTBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]Technology appraisal guidanceTBC
Breast cancer guidelinesNICE guidelineTBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]Technology appraisal guidance
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All